Kala Pharmaceuticals Inc (KALA) Major Shareholder Buys $2,185,436.54 in Stock

Kala Pharmaceuticals Inc (NASDAQ:KALA) major shareholder Orbimed Advisors Llc purchased 170,338 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The stock was purchased at an average price of $12.83 per share, with a total value of $2,185,436.54. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Friday, January 12th, Orbimed Advisors Llc acquired 240,484 shares of Kala Pharmaceuticals stock. The shares were bought at an average price of $13.28 per share, with a total value of $3,193,627.52.

Shares of Kala Pharmaceuticals Inc (KALA) traded up $1.75 during trading hours on Friday, hitting $15.60. 386,703 shares of the stock traded hands, compared to its average volume of 457,226. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. Kala Pharmaceuticals Inc has a twelve month low of $11.81 and a twelve month high of $26.75.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.14). equities research analysts forecast that Kala Pharmaceuticals Inc will post -2.22 EPS for the current year.

Several analysts have recently weighed in on the stock. BidaskClub upgraded shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Co restated a “buy” rating on shares of Kala Pharmaceuticals in a research report on Friday, January 5th. Wedbush restated an “outperform” rating and set a $46.00 price objective on shares of Kala Pharmaceuticals in a research report on Friday, December 22nd. JPMorgan Chase & Co. set a $35.00 price objective on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 19th. Finally, Zacks Investment Research downgraded shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $36.80.

Several institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP acquired a new position in shares of Kala Pharmaceuticals in the 3rd quarter valued at $222,000. Neuberger Berman Group LLC acquired a new position in shares of Kala Pharmaceuticals in the 3rd quarter valued at $1,142,000. Cubist Systematic Strategies LLC acquired a new position in shares of Kala Pharmaceuticals in the 3rd quarter valued at $228,000. Crestline Management LP acquired a new position in shares of Kala Pharmaceuticals in the 3rd quarter valued at $888,000. Finally, Orbimed Advisors LLC acquired a new position in shares of Kala Pharmaceuticals in the 3rd quarter valued at $54,251,000. 62.96% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.themarketsdaily.com/2018/01/13/kala-pharmaceuticals-inc-kala-major-shareholder-buys-2185436-54-in-stock.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply